Panobinostat Post Authorization Safety Study, a non-interventional study of panobinostat in combination with bortezomib and dexamethasone in patients with Relapsed and/or Refractory Multiple Myeloma (RRMM) First published 01/05/2017 Last updated 02/07/2024 EU PAS number:EUPAS18261 Study Finalised